Skip to content

Ketamine: all studies

Page 217 of 449: studies 2,161 to 2,170 of 4,486, newest first. Back to the ketamine overview

Research

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.

Journal of Psychopharmacology February 1, 2021 Rebecca L Rothberg, Nour Azhari, Nancy A Haug et al. 95 citations

Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary...

Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.

Journal of Psychopharmacology February 1, 2021 Dylan Truppman Lattie, Hayley Nehoff, Shona Neehoff et al. 13 citations

Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders. This study aimed to assess changes following acute and maintenance ketamine therapy on the Fear Questionnaire (FQ) subscales and the Spielberger State Anxiety Inventory (SSAI). This secondary analysis used data from a mixed open-label and...

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Psychopharmacology January 22, 2021 J. Siegel, Ben J Palanca, Beau M Ances et al. 53 citations

Ketamine produces a rapid antidepressant response in over 50% of adults with treatment-resistant depression. A long infusion of ketamine may provide durable remission of depressive symptoms, but the safety, efficacy, and neurobiological correlates are unknown. In this open-label, proof-of-principle study, adults with treatment-resistant depression (N = 23) underwent a 96-h infusion of...

The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression

Frontiers in Psychiatry January 20, 2021 Conor McDonnell, F. Dunphy-Doherty, J. Rouine et al.

Major depressive disorder (MDD) is the leading cause of disability worldwide. The majority of antidepressant drugs require several weeks or months of treatment to demonstrate efficacy and a subset of patients are resistant to such interventions. Ketamine demonstrates rapid and long-lasting antidepressant effects in treatment resistant patients; however, side effects may limit its widespread...

Behavioral effects of sub-anesthetic ketamine in a go/no-go task

Journal of Psychedelic Studies January 15, 2021 André S. Nilsen, Bjørn E. Juel, Nadine Farnes et al.

While psychedelic agents are known to have powerful, but largely unexplained, effects on contents of consciousness, there is an increasing interest in the potential clinical usefulness of such drugs for therapy, and legalization is discussed in some countries. Thus, it is relevant to study the effects of psychedelic compounds not only on experience, but also on behavioral performance.Seven...

A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ project

Journal of Affective Disorders Reports January 15, 2021 Chris Griffiths, Kate Walker, Isabel Reid et al. 26 citations

There has been a lack of in-depth interviews investigating patient experience of ketamine treatment for depression. We examined participants’ pathways to receiving ketamine infusion to treat their depression, and their responses to, lived experiences of, and attitudes towards ketamine treatment. Qualitative methods were used to conduct in-depth interviews with 13 patients (6 male; 7 female)...

DOI: 10.1016/j.jadr.2021.100079 (opens in new tab) Ketamine Dissociative Depression economics Clinical psychology +9

Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice.

Pharmacology, Biochemistry, and Behavior January 12, 2021 Tianhao Gao, Rongjun Ni, Shasha Liu et al.

Ketamine, a dissociative anaesthetic, has been used in the treatment of major depressive disorder (MDD) as a rapid acting antidepressant drug. Recent studies have shown that ketamine may increase the potential risk of treatment-induced mania in MDD patients. Lithium is a well-known mood stabilizer and has been widely used for the treatment of mania. It is not fully understood which forebrain...

Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms.

Biological Psychiatry January 8, 2021 Mingzheng Wu, Samuel Minkowicz, V. Dumrongprechachan et al. 96 citations

BACKGROUND Ketamine elicits rapid onset antidepressant effects in patients with clinical depression through mechanisms hypothesized to involve the genesis of neocortical dendritic spines and synapses. Yet, the observed changes in dendritic spine morphology usually emerge well after ketamine clearance, raising questions about the link between rapid behavioral effects of ketamine and plasticity....

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.

American Journal of Psychiatry January 5, 2021 Adriana Feder, Sara Costi, Sarah B. Rutter et al. 239 citations

OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first...

The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 2, 2021 Agnieszka Pałucha-Poniewiera, K. Podkowa, Anna Rafało-Ulińska

Ketamine produces a rapid antidepressant effect, but its use can be associated with serious side effects. Hence, other therapeutic options that will allow us to obtain a quick and safe antidepressant effect by modulating glutamatergic transmission are needed. Antagonists of mGlu2/3 receptors, which share some mechanisms of action with ketamine, may be good candidates to obtain this effect....